<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000830.v1.p1" parentStudy="phs000830.v1.p1" createDate="2014-11-06" modDate="2014-11-06">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Raymond J. Cho, MD, PhD</td><td>University of California, San Francisco, CA, USA</td></tr>
		<tr><td>Co-Investigator</td><td>Joe Gray, PhD</td><td>Oregon Health Sciences University, OR, USA</td></tr>
		<tr><td>Funding Source</td><td>K08-CA169865</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>U54 CA112970</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>XPC and Non-XPC Cutaneous Squamous Cell Carcinoma Mutation Rate Study</StudyNameEntrez>
	<StudyNameReportPage>Xeroderma Pigmentosum, Complementation Group C, (XPC) and Non-XPC Cutaneous Squamous Cell Carcinoma (cSCC) Mutation Rate Study</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Cohort</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Base mutations occur at higher frequencies within heterochromatin and late-replicating DNA. In this study, we show that regional differences in mutation frequency are absent in portions of the genome that are not transcribed within cutaneous squamous cell carcinomas (cSCCs) with an XPC-\- genetic background. The XPC-\- genetic background predicates a loss of global genome nucleotide excision repair (GG-NER), thus our data shows that regional differences in mutation frequency are a result of differential access of DNA repair protein. Unexpectedly, we also note that greater transcription reduces mutations on both strands of genes in heterochromatin, and only to those levels observed in euchromatin, in a XPC-dependent fashion. Therefore, transcription likely reduces mutation prevalence by increasing access to DNA repair proteins. This tripartite relationship between DNA repair, transcription, and chromatin state shows a new cancer risk factor in human populations.</p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Zheng CL, Wang NJ, Chung J, Moslehi H, Sanborn JZ, Hur JS, Collisson EA, Vemula SS, Naujokas A, Chiotti KE, Cheng JB, 			Fassihi H, Blumberg AJ, Bailey CV, Fudem GM, Mihm FG, Cunningham BB, Neuhaus IM, Oh DO, Cleaver JE, Liao W, LeBoit PE, Costello JF, 			Lehmann AR, Gray JW, Spellman PT, Arron ST, Huh N, Purdom E, Cho RJ." title="Transcription restores DNA repair to heterochromatin, determining mutation rates in cancer genomes" journal="Cell Reports, in press"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Xeroderma Pigmentosum, Complementation Group C"/>
		<Disease vocab_source="MESH" vocab_term="Carcinoma, Squamous Cell"/>
		<Disease vocab_source="MESH" vocab_term="Skin Neoplasms"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Raymond J. Cho, MD, PhD</AttName>
			<Institution>University of California, San Francisco, CA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>K08-CA169865</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U54 CA112970</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Joe Gray, PhD</AttName>
			<Institution>Oregon Health Sciences University, OR, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="2" shortName="DS-SKCA-MDS" longName="Disease-Specific (Skin Cancer, MDS)"/>
		<ConsentGroup groupNum="3" shortName="DS-CA-MDS" longName="Disease-Specific (Cancer, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000830.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000830.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000830.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Disease-Specific (Skin Cancer, MDS)</ConsentName>
        <ConsentAbbrev>DS-SKCA-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Skin Cancer.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="3">
        <ConsentName>Disease-Specific (Cancer, MDS)</ConsentName>
        <ConsentAbbrev>DS-CA-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Cancer.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
